Ascentage Pharma is an integrated global biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet …

6 days ago · China-based biotech Ascentage Pharma has raised $126m in a US initial public offering (IPO), marking the first biotech IPO of 2025. The company sold 7,325,000 American …

Ascentage Pharma Group International Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.

6 days ago · Ascentage Pharma, a China-based drug developer with global ambitions, now has $126.4 million from a U.S. IPO that will mainly support late-stage clinical development of two …

1 day ago · Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical …

3 days ago · Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule …

Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in …

6 days ago · Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million …

4 days ago · ROCKVILLE, MD, the United States, and SUZHOU, China, December 10, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in …

Jun 14, 2024 · Ascentage Pharma is investigating olverembatinib in multiple clinical studies in several types of cancer. Olverembatinib has been granted orphan drug designation and Fast …